Anaphylaxis is an acute multisystem syndrome that results from rapid and diffuse release of vasoactive mediators, cytokines, and enzymes by myeloid cells minutes to hours after exposure to an inciting trigger. In mice anaphylaxis can be induced through both the classical and alternative pathways. [1] [2] [3] The classical pathway depends on IgE-mediated activation of the highaffinity FcεRI on mast cells and basophils, whereas the alternative pathway depends on IgG-mediated activation of multiple myeloid cell types through Fcg receptors (FcgRs), particularly FcgRIII. The classical pathway is well-established in human subjects, whereas the importance of the alternative pathway in human subjects is supported by considerable but not conclusive evidence. 4 FcgRs regulate innate and adaptive immune responses in a coordinated manner that involves positive signals that activate cells and cause proinflammatory responses, as well as negative signals that suppress cellular activation and inflammation. Dysregulation of FcgR-mediated signaling has been implicated in wide-ranging disease processes. [5] [6] [7] [8] [9] Murine stimulatory FcgRs include FcgRI (expressed by dendritic cells and mononuclear cell subpopulations in peripheral blood), FcgRIII (expressed in varying degrees by all peripheral blood myeloid cells), and FcgRIV (expressed by neutrophils and peripheral blood monocytes and dendritic cells). 6, 10 Activating FcgRs contain the immunoreceptor tyrosine-based activation domain (ITAM) on the Fc receptor g chain (FcRg). On the other hand, FcgRIIB is inhibitory because it lacks FcRg but contains a cytosolic immunoreceptor tyrosine-based inhibitory domain (ITIM) domain. 6, 9, 11, 12 Given the central role of murine activating FcgRs in IgGmediated anaphylaxis and in several autoimmune and inflammatory disorders, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] the identification of a therapeutic strategy to modulate cell stimulation through FcgRs would have potential wide-ranging therapeutic implications. We previously characterized a mouse model of IgG-mediated anaphylaxis triggered by 2.4G2, a rat IgG 2b mAb that directly binds to and blocks both FcgRIII and FcgRIIB but also inhibits stimulation of mouse myeloid cells through FcgRI and FcgRIV. [23] [24] [25] Our data suggest that 2.4G2 inhibition of FcgRI and FcgRIV results from an interaction between 2.4G2's Fc domains and these receptors.
These observations raised questions about the likely effects of injecting mice with an mAb that only binds to FcgRIIB, such as the mouse IgG 2a allo-mAb K9.361. 26 Theoretically, this mAb can inactivate myeloid cells by directly transmitting negative signals through FcgRIIB, although most evidence suggests that FcgRIIB prevents signaling through stimulatory receptors to which it has been cross-linked rather than by directly making cells refractory to other signals. 27 Alternatively, K9.361 might increase the sensitivity of myeloid cells to subsequent ligation of their stimulatory receptors by blocking IgG-associated ligand cross-linking of the stimulatory receptors to FcgRIIB. A third possibility is that K9.361 might bind to stimulatory FcgRs through its Fc domains and affect the expression, responsiveness, or both of those receptors.
Distinguishing among these possibilities would provide insight into the mechanisms involved in inhibitory receptor function and the interactions among stimulatory and inhibitory receptors and might also suggest strategies for suppressing anaphylaxis and other inflammatory disorders. Consequently, we investigated the effects of injecting mice with K9.361 and its F(ab9) 2 fragment, which should be capable of binding to and cross-linking FcgRIIB but lacks the Fc domains required to interact with other FcgRs. Our results indicate that K9.361 indirectly induces mild anaphylaxis through an Fc-dependent interaction with FcgRIII and then blocks active and passive IgG-mediated but not IgE-mediated anaphylaxis. In addition, treatment with K9.361 and its F(ab9) 2 fragment provides an approach to safely inhibit IgG-mediated anaphylaxis.
METHODS Mice
Male and female BALB/c and C57BL/6 mice were purchased from Taconic (Hudson, NY) and used at 7 to 15 weeks of age. Some experiments also used BALB/c mice that were bred in house. FcgRI-and FcgRIII-deficient mice on a C57BL/6 background were originally obtained from Jeffrey Ravetch (Rockefeller University, New York, NY); these mice were bred to each other to generate mice deficient in both FcgRI and FcgRIII. F2 offspring were typed by using PCR to identify double-deficient offspring. FcgRIIB-deficient mice and FcRg chain-deficient mice on a BALB/c background were purchased from Jackson Laboratories (Bar Harbor, Me). IgE-deficient mice on a BALB/c background were a gift of Hans Oettgen (Boston Children's Hospital, Boston, Mass). All transgenic mice were bred in house.
BALB/c female mice, 6 to 8 weeks old, were treated intratracheally 3 times per week for 3 weeks with chicken egg white (EW) protein and assessed for airway hypersensitivity by using Buxco with gradient methacholine challenge. EW-sensitized mice were subsequently challenged by means of oral gavage with 100 mg of protein and assessed for temperature decrease and diarrhea and then grouped according to the severity of sensitization. Shozo Izui, University of Geneva, Geneva, Switzerland; mouse IgE anti-TNP, ATCC). Monoclonal antibodies produced as ascites in pristane-primed athymic nude mice were purified, as previously described. 28 A goat antiserum to mouse IgD was produced, as previously described. 28 Ovalbumin (OVA) was purchased from Sigma (St Louis, Mo). OVA was labeled with 2,4,6-trinitrophenyl-ε-aminocaproyl-O-succinamide (TNP-OSu; Biosearch Technologies, Petaluma, Calif). Biotinylation was achieved by alkalizing stock mAb in NaHCO 3 at a pH of 8.0 and then mixing mAb with EZ Link biotin (Thermo Scientific, Waltham, Mass) at a 10:1 weight ratio for 2 hours at room temperature, followed by dialysis against normal saline. Propranolol was obtained from Hikma Pharmaceuticals (London, United Kingdom). Histamine ELISA kits were purchased from IBL-America (Minneapolis, Minn).
Antibodies, antigens, and pharmaceuticals
Preparation of F(ab9) 2 fragments K9.361 and 2.4G2 mAbs were digested for 7.5 hours at 378C with immobilized pepsin (Thermo Scientific) while being rotated and then purified with the NAb Protein A Plus column (Thermo Scientific) and concentrated with centrifugal filter devices (Amicon, EMD Millipore, Norwood, Ohio). Aliquots were compared with undigested intact mAb under nonreducing conditions by using SDS-PAGE with 7% polyacrylamide gels (NuPAGE Tris-Acetate; Life Technologies, Grand Island, NY) and lacked detectable intact IgG (see Fig E1 in this article's Online Repository at www. jacionline.org). 25 
Detection of systemic anaphylaxis
Mice were challenged intravenously with the appropriate triggering antibody or antigen, after which serial body temperatures were determined every 5 to 15 minutes for at least 1 hour with a rectal probe to follow and quantify hypothermia, a sign of shock. 13 Similar results were seen in male and female mice.
Preparation of nucleated cells
Blood obtained by means of tail vein incision was collected in microtainers that contained K 2 EDTA (BD Biosciences, San Jose, Calif). Red blood cells were lysed with ammonium-chloride-potassium lysis buffer; cells were washed twice with ice-cold HN (filtered Hanks' buffer containing 10% newborn calf serum), maintained at 48C, and resuspended in HNA (HN plus 0.2% NaN 3 ). Single-splenocyte suspensions were prepared, as previously described. 29 
Immunofluorescence staining
Peripheral blood cells ( In some experiments cells were incubated at 48C with 10 mg of unlabeled K9.361 before staining as an additional negative control. Cells were washed twice after staining, fixed with 2% to 4% paraformaldehyde, and analyzed with an LSR II (BD Biosciences), and data were analyzed by using FACSDiva software. Similar results were generated by using cells obtained from male and female mice.
Statistics
One-tailed Mann-Whitney U tests or 1-way ANOVA with Bonferroni multiple comparison posttesting were calculated to test for statistical significance.
RESULTS

Anti-FcgRIIB mAb induces FcgRIII-dependent anaphylaxis
Our previous studies demonstrated that 2.4G2 (an mAb that binds to both the stimulatory FcgRIII and the inhibitory FcgRIIB) induces FcgRIII-dependent anaphylaxis that is manifested as shock-associated hypothermia. In contrast, we expected that K9.361, a mouse IgG 2a allo-mAb that only binds directly to FcgRIIB, would block this receptor and possibly transmit a negative signal to FcgRIIB-expressing cells without inducing anaphylaxis. Surprisingly, a small temperature decrease rapidly developed in BALB/c mice injected with this mAb (Fig 1, A) . Because the temperature decrease was not always greater than that observed in mice injected with saline or isotype-control mAbs, we pretreated mice with the b-adrenergic receptor antagonist propranolol, which prevents compensatory mechanisms that minimize anaphylaxis severity, 31 to determine whether this would make anaphylaxis easier to appreciate. Indeed, propranolol-pretreated mice had an approximately 48C decrease in rectal temperature in response to intravenous anti-FcgRIIB mAb (Fig 1, A) but did not have hypothermia in response to intravenous saline or intravenous injection of a mouse IgG 2a alloantibody to H-2K d (SF-1.1.1.10; Fig 1, B) . To support the interpretation that propranolol acts to suppress downstream compensatory mechanisms and not to enhance upstream mediator release, mice were treated with propranolol or saline and subsequently challenged with K9.361, the IgG 2a isotype control mAb CBPC-101, or EM95 (rat IgG 2a anti-IgE mAb used as a positive control for the capacity to induce histamine release). In fact, propranolol-treated mice had lower levels of plasma histamine on K9.361 challenge (see Fig E2 in this article's Online Repository at www.jacionline.org). AntiFcgRIIB mAb induced anaphylaxis in propranolol-pretreated C57BL/6 mice, as well as BALB/c wild-type (WT) mice, but not in propranolol-pretreated BALB/c background mice that lack FcRg (a required component of all stimulatory FcRs) or FcgRIIB or in C57BL/6 background FcgRIII-deficient mice or FcgRI/RIII double-deficient mice (Fig 1, C) .
Taken together, these observations suggest that induction of anaphylaxis by anti-FcgRIIB mAb requires 2 interactions: with FcgRIIB through its antigen-binding site and with FcgRIII through its Fc domain. To confirm this, we compared the abilities of intact anti-FcgRIIB mAb and equimolar amounts of its F(ab9) 2 fragment to induce hypothermia in propranolol-pretreated mice: only the d mAb or 500 mg of K9.361. C, BALB/c background WT, FcRg-deficient, and FcgRIIB-deficient and C57BL/6 background WT, FcgRIII-deficient, and FcgRI/RIII double-deficient mice were pretreated with propranolol and then injected intravenously with 500 mg of K9.361. D, BALB/c mice were pretreated with propranolol and then injected intravenously with 375 mg or 3.75 mg of intact K9.361 mAb or 250 mg of 2.5 mg of the F(ab9) 2 fragment of K9.361. Injection of 5 mg of the F(ab9) 2 fragment of mAb K9.361 was also performed and did not induce hypothermia (not shown). E, BALB/c mice were pretreated with propranolol and then injected intravenously with 100 mg of intact 2.4G2 rat IgG 2b anti-mouse FcgRIIB/RIII mAb, 500 mg of the F(ab9) 2 fragment of 2.4G2, or 100 mg of M1/70 rat IgG 2b anti-mouse CD11b mAb. Skulls indicate deaths of individual mice. Means 6 SEMs (n 5 4) for serial rectal temperatures over 1 to 2 hours are shown. Similar results were seen in male and female mice.
intact form of this mAb had this effect, even when we varied the quantities of the intact mAb and its F(ab9) 2 fragment over a 10-fold range (Fig 1, D) . In contrast, the F(ab9) 2 fragment of 2.4G2 induced hypothermia in propranolol-pretreated mice, although it was considerably less severe hypothermia than with intact 2.4G2, whereas the intact rat IgG 2b anti-CD11b mAb M1/70, which binds to most myeloid cells and also suppresses stimulatory FcgR expression, 25 induced less severe hypothermia in these mice than either intact 2.4G2 or its F(ab9) 2 fragment (Fig 1, E, 
In vivo effects of anti-FcgRIIB mAb on FcgR expression
Failure of the F(ab9) 2 fragment of K9.361 anti-mouse FcgRIIB mAb to induce anaphylaxis did not result from a loss of binding activity inasmuch as it was more potent on a weight basis than intact K9.361 at blocking the binding of fluorochrome-labeled intact K9.361 to FcgRIIB 1 spleen cells in vitro (Fig 2, A) . Consistent with this, compared with injection with CBPC-101, injection of WT BALB/c mice with intact K9.361 or its F(ab9) 2 fragment suppressed ex vivo FcgRIIB staining of peripheral blood monocytes, neutrophils, and basophils (the 3 cell types implicated in IgG-mediated anaphylaxis; Fig 2, B , and see Fig E4, A, in this article's Online Repository at www.jacionline.org). 1, 25 Note that mice were injected with 500 mg of intact K9.361 but 1 mg of the F(ab9) 2 fragment to partially compensate for the decreased in vivo half-life of F(ab9) 2 . 32 Intact K9.361 was only slightly more effective than the F(ab9) 2 fragment of this mAb at blocking ex vivo staining with intact fluorochrome-labeled K9.361, and similar suppression was observed 6 and 24 hours after injection of intact K9.361 or its F(ab9) 2 fragment, although relatively little Intact K9.361 also differed from its F(ab9) 2 fragment in that only the former decreased the total quantity of FcgRIIB on myeloid cells after in vivo injection (Fig 2, C , and see Fig E4, B) . In contrast to intact anti-FcgRIIB mAb, the intact IgG 2a anti-H-2 K d allo-mAb SF-1.1.1.10 had no effect on expression of its ligand on myeloid cells.
In addition to decreasing FcgRIIB expression, intact K9.361 also induced loss of most FcgRIII on myeloid cells in vivo, an effect not observed in FcgRIIB-deficient mice, indicating that anti-FcgRIIB mAb binding to cells through its antigen-binding site is essential for its downmodulation of FcgRIII (Fig 2, D , and see Fig E4, C) . As predicted, the F(ab9) 2 fragment of anti-FcgRIIB mAb and intact CBPC-101 had no in vivo effect on the expression of FcgRIII (Fig 2, E, and see Fig E4, D) . Intact mouse IgG 2a anti-H-2K d mAb also had no effect on FcgRIII expression, even though its Fc domains should be able to interact with this receptor (Fig 2, E , and see Fig E4, D) .
An additional experiment evaluated the ability of intact anti-FcgRIIB mAb to affect expression of FcgRI and FcgRIV, which are expressed on some mononuclear populations and on mononuclear cells, as well as neutrophils, respectively. 10 Although there appeared to be some decreases in expression of these stimulatory FcgRs (Fig 2, F) , they were variable, cell type dependent, and considerably less than those observed for FcgRIII. This might reflect the higher affinity of FcgRI and FcgRIV than FcgRIII for uncomplexed IgG antibody molecules, 10,30 which would allow endogenous serum IgG to better inhibit an interaction between the Fc of FcgRIIB-bound K9.361 with FcgRI and FcgRIV than with FcgRIII.
Inhibition of anaphylaxis by anti-FcgRIIB mAb
The ability of the F(ab9) 2 fragment of K9.361 to bind to FcgRIIB without interacting with stimulatory FcgRs or inducing anaphylaxis, even in propranolol-pretreated mice, and the ability of intact K9.361 to cross-link FcgRIIB, modulate most FcgRIII from myeloid cells, and induce mild anaphylaxis suggested that they might differ in their abilities to inhibit subsequent FcgR-mediated anaphylaxis. To test this, we first treated WT mice with 1 mg of the F(ab9) 2 fragment of K9.361 and then, 6 or 24 hours later, treated these mice with propranolol and injected them with intact K9.361. Pretreatment with the F(ab9) 2 fragment of K9.361 strongly suppressed the anaphylactic response to intact K9.361 6 hours later and totally blocked anaphylaxis when the intact mAb was injected 24 hours after the F(ab9) 2 fragment (Fig 3, A) . In contrast, pretreatment of WT mice with intact K9.361 but not with its F(ab9) 2 fragment suppressed completely the hypothermia response to intact 2.4G2 (anti-FcgRIIB/RIII mAb) in mice that were not treated with propranolol (Fig 3, B) . As expected, K9.361 suppression of the anaphylactic response to 2.4G2 was FcgRIIB dependent (Fig 3, C) , reflecting the FcgRIIB requirement for K9.361 binding to cells and was dose dependent (Fig 3, D) . A single injection of intact K9.361 suppressed the anaphylactic response to 2.4G2, even when 2.4G2 was given in the presence of propranolol, for at least 3 days (Fig 3, E) . K9.361 significantly suppressed 2.4G2-mediated anaphylaxis 6 hours after intravenous injection and protection increased 24 hours after injection (Fig 3, F) .
These observations suggest that suppression of the anaphylactic response to 2.4G2 might be accomplished without even the mild anaphylaxis that is induced by intact K9.361 by serially injecting mice with F(ab9) 2 of K9.361, then intact K9.361, and finally 2.4G2. This was indeed the case. Even in mice that were treated with propranolol, initial treatment with F(ab9) 2 of K9.361 did not diminish the ability of intact K9.361 to inhibit 2.4G2-induced hypothermia (Fig 3, G) .
Intact anti-FcgRIIB mAb blocks active and passive IgG-mediated anaphylaxis
Suppression of 2.4G2-induced anaphylaxis by pretreatment with intact K9.361 but not its F(ab9) 2 fragment suggested that treatment with intact anti-FcgRIIB mAb might be able to suppress antigen-induced IgG-mediated anaphylaxis. To test this, mice were pretreated with 500 mg of intact K9.361 or CBPC-101 or 1 mg of the F(ab9) 2 fragment of K9.361. Twenty-two hours later, mice were passively sensitized for IgG-mediated anaphylaxis by means of injection of 500 mg of IgG 1 or IgG 2a anti-TNP mAb and then challenged intravenously 2 hours later with 100 mg of TNP-OVA in the absence of propranolol. Pretreatment with intact K9.361 completely suppressed IgG 1 -and IgG 2a -mediated anaphylaxis, whereas pretreatment with the F(ab9) 2 fragment of K9.361 had no effect on the anaphylactic response (Fig 4, A) . BALB/c background IgE-deficient mice were immunized with goat anti-mouse IgD antiserum, which stimulates a very large IgG 1 anti-goat IgG antibody response, to determine whether intact K9.361 would also suppress IgG-mediated anaphylaxis in actively sensitized mice. 33, 34 Thirteen days later, mice were treated with 500 mg of intact K9.361 or CBPC-101 and then challenged intravenously 1 day after that with 100 mg of goat IgG. Severe anaphylaxis developed in the mice that had been treated with the control mAb, whereas no hypothermia was seen in the K9.361-treated mice (Fig 4, B) .
Because FcgRIIB is present on mast cells and basophils and can inhibit IgE-mediated anaphylaxis, we determined whether K9.361 can suppress or exacerbate IgE-mediated anaphylaxis. BALB/c WT mice were treated with 500 mg of K9.361 or CBPC-101 and then passively sensitized 20 hours later by means of intravenous injection of 500 mg of IgG 1 anti-TNP or 10 mg of IgE anti-TNP and challenged intravenously 4 hours later with 100 mg of TNP-OVA. K9.361 protected against IgG 1 -mediated anaphylaxis but not IgE-mediated anaphylaxis (Fig 4, C) .
Because the binding of IgG-containing immune complexes to FcgRIIB can suppress IgE-mediated anaphylaxis, it was possible that K9.361 blocking of FcgRIIB might exacerbate IgE-mediated anaphylaxis in an active sensitization model in which mice produced both IgG and IgE antibodies to the immunogen. To evaluate this, we studied mice that had been sensitized intratracheally with EW and then challenged repeatedly with EW by means of oral gavage until they had both diarrhea and hypothermia in response to oral gavage EW. Although mice immunized by using this protocol generate both IgE and IgG anti-EW antibodies, the diarrhea and hypothermia responses to oral EW challenge are entirely IgE dependent. Intravenous treatment of these mice with EW allergy with 500 mg of K9.361, followed 24 hours later by oral gavage with 100 mg of EW, slightly ameliorated anaphylaxis severity (Fig 4, D) .
DISCUSSION
Anaphylaxis is induced in mice and most likely in human subjects through aggregation of stimulatory FcgRs by IgG-containing immune complexes. 4 We have now shown that K9.361, an IgG 2a mAb that binds to and cross-links the inhibitory receptor FcgRIIB, also induces mild anaphylaxis, which becomes severe when homeostatic compensatory mechanisms that depend on b-adrenergic receptors are blocked. Induction of anaphylaxis requires binding of K9.361 to cells through its antigen-binding site because this mAb does not induce anaphylaxis in FcgRIIB- Mice were injected intravenously 6 or 24 hours later with propranolol, followed 15 minutes later by intravenous injection of 500 mg of intact K9.361. B, BALB/c mice (4 per group) were injected intravenously with 500 mg of intact CBPC-101 or K9.361 or with 5 mg of the F(ab9) 2 fragment of K9.361. Mice were challenged intravenously 24 hours later with 500 mg of 2.4G2. C, BALB/c background WT and FcgRIIB-deficient mice (4 per group) were pretreated by means of intravenous injection with 500 mg of intact CBPC-101 or K9.361 and challenged intravenously 24 hours later with 500 mg of 2.4G2. In Fig 3, A-C, Rectal temperatures were followed for the next hour after challenge, and means 6 SEMs are shown. D, BALB/c mice (3 per group) were injected intravenously with the doses of K9.361 shown and challenged 24 hours later with 500 mg of 2.4G2. Maximum temperature decreases 6 SEM during the following hour are shown. E, BALB/c mice (4 per group) were injected intravenously with 500 mg of intact CBPC-101 or K9.361 followed 24, 48, or 72 hours later by intravenous injection of propranolol and 15 minutes later by intravenous injection of 100 mg of 2.4G2. Rectal temperatures were followed for the next 2 hours, and mean 6 SEM maximum temperature decreases are shown. F, BALB/c mice (4 per group) were injected intravenously with 500 mg of intact CBPC-101 or K9.361, followed 6 or 24 hours later by intravenous injection of 500 mg of 2.4G2. Rectal temperatures were followed for the next hour, and means 6 SEM are shown. G, BALB/c mice (3 per group) were injected intravenously with saline or 1 mg of the F(ab9) 2 fragment of K9.361. Twenty-four hours later, mice were injected intravenously with 500 mg of intact CBPC-101 or K9.361. After an additional 24 hours, mice were injected intravenously with propranolol, followed 15 minutes later by intravenous injection of 100 mg of 2.4G2. Rectal temperatures were followed for the next hour, and means 6 SEMs are shown. Skulls indicate individual mouse deaths. deficient mice. It also requires binding to FcgRIII through this mAb's Fc domain because it does not induce anaphylaxis in FcgRIII-or FcgR-deficient mice. The induction of anaphylaxis by K9.361 is accompanied by and probably depends on FcgRIII cross-linking because this mAb both decreases the quantity of FcgRIIB expressed by myeloid cells and removes approximately 80% of FcgRIII from these cells, whereas its F(ab9) 2 fragment, which does not induce anaphylaxis, has neither effect. This dependence on stimulatory FcgR cross-linking is also suggested by the inability of SF-1.1.1.10, an IgG 2a mAb to H-2K d (an antigen that is strongly expressed by cells that express FcgRIIB), to induce anaphylaxis or decrease the expression of H-2K d or FcgRIII on myeloid cells (Figs 1, B ; 2, C; and 2, E).
Although previous studies have shown that mAbs that bind to one FcgR or other cell-surface targets can interact with other FcgRs through their Fc domains and that this can affect cell function, 25, [35] [36] [37] [38] [39] ours provides the first evidence that antibody binding of an inhibitory receptor through the antibody's F(ab) domain can activate cells through an interaction between that antibody's Fc domain and a stimulatory receptor. These observations have important implications for the clinical use of IgG mAbs to cell membrane molecules that can also interact with stimulatory FcgRs on those cells. Our observations also demonstrate that even though FcgRIIB inhibits cell signaling through activation of its ITIM, these inhibitory effects in our model are inadequate to totally suppress anaphylaxis if FcgRIII is also activated. Thus the stimulatory signaling of the FcgRIIIassociated ITAM can dominate the inhibitory effects of the FcgRIIB-associated ITIM.
Our observations also establish the ability of the K9.361 anti-FcgRIIB mAb to inhibit anti-FcgRIIB/RIII mAb (2.4G2)-induced anaphylaxis, as well as IgG-mediated anaphylaxis induced by antigen challenge of actively or passively sensitized mice. More than 1 mechanism can be involved in this suppressive effect. First, the loss of approximately 80% of FcgRIII by myeloid cells in K9.361-treated mice might diminish the ability of FcgRIII cross-linking to induce anaphylaxis. However, this effect is probably not sufficient to suppress IgG-mediated anaphylaxis because treating mice with M1/70 rat IgG 2b anti-mouse CD11b mAb does not inhibit IgG-mediated anaphylaxis, even though it substantially decreases myeloid cell FcgRIII expression. 25 Additional possible mechanisms for suppression of IgGmediated anaphylaxis are (1) negative signaling through FcgRIIB or (2) anergy induction by co-cross-linking of FcgRIIB with FcgRIII, thereby establishing a refractory state with potentially fewer available mediators for secretion. These possibilities are consistent with the considerable time required for maximal suppression of 2.4G2-induced anaphylaxis by K9.361 (greater after 24 hours than after 6 hours; Fig 3, F) and might in part explain K9.361-mediated protection in IgE-mediated anaphylaxis to food protein challenge (Fig 4, D) .
The inhibitory effects of FcgRIIB generally depend on coaggregation of this inhibitory receptor with stimulatory receptors through a common surface ligand and the ensuing recruitment of SH2-containing inositol polyphosphate-5-phosphatase 1, which terminates ITAM-induced phosphoinositide 3-kinase-mediated signaling. 40, 41 This might explain the failure of intact K9.361 to strongly suppress IgE-mediated anaphylaxis (Fig 4, C) . Although this mAb binds FcgRIIB, which is expressed on mouse basophils and mast cells, its Fc domains will not interact with the FcgRI on these cells. Because mouse mast cells and basophils also express FcgRIII, which mediates the participation of these cells in IgG-mediated anaphylaxis, the strong suppression of IgG-but not IgE-mediated anaphylaxis by K9.361 suggests that this suppression is stimulatory Fc receptor specific rather than a result of global desensitization of specific cell types.
The inability of the F(ab9) 2 fragment of K9.361 to suppress IgG-mediated anaphylaxis could reflect its failure to bind to and activate FcgRIII to decrease FcgRIII expression and/or its limited ability to activate SH2-containing inositol polyphosphate-5-phosphatase 1 by cross-linking FcgRIIB. Although the F(ab9) 2 fragment of an IgG antibody, like the intact antibody, is divalent and consequently has the potential to cross-link its ligand, F(ab9) 2 fragments of IgG antibodies are less potent than intact IgG antibodies at cross-linking their ligands in vivo. 39 The aggregation of IgG-bound molecules on one cell is enhanced by IgG-Fc interactions with FcgRs on adjacent cells and by Fc-dependent interactions with C1q. 42 The greater cross-linking ability of intact K9.361 than its F(ab9) 2 fragment is most likely required for the intact antibody's ability to decrease FcgRIIB and FcgRIII expression (Fig 2, B) through the endocytosis of antibody receptor aggregates.
One result of our study that is somewhat difficult to explain is the ability of the F(ab9) 2 fragment of K9.361 to cause relatively slow (>6 hours) time-dependent suppression of the response to intact K9.361 (Fig 3, A) without suppressing the anaphylactic response to 2.4G2 (Fig 3, B) or antigen-induced and IgG-mediated anaphylaxis (Fig 4, A) .
The time dependence of the suppressive effect cannot be explained by the time required for the F(ab9) 2 fragment to saturate its ligand because blocking of intact K9.361 binding to myeloid cells is at least as great 6 hours after F(ab9) 2 injection as it is 18 hours later (Fig 2, B) , when suppression of anaphylaxis induction by intact K9.361 is considerably greater (Fig 3, A) . It is possible that F(ab9) 2 binding to FcgRIIB in the absence of FcgRIIB cross-linking to a stimulatory receptor has a cumulative suppressive effect on subsequent activation of stimulatory receptors, including FcgRIII. However, the failure of 24 hours of treatment with the F(ab9) 2 fragment of K9.361 to inhibit FcgRIII-dependent anaphylaxis induction by 2.4G2 suggests that this putative inhibitory effect would have to be quite limited. An alternative possibility is that cross-linking of FcgRIIB by the F(ab9) 2 fragment of K9.361 physically separates FcgRIIB from FcgRIII on the cell membrane, so that the Fc domain of intact K9.361 that has bound to FcgRIIB is less likely to bind FcgRIII.
Regardless of the explanation for this phenomenon, the ability of the F(ab9) 2 fragment of K9.361 to prevent any anaphylactic response to intact K9.361 and the ability of intact K9.361 to prevent antigen-induced and IgG-mediated anaphylaxis suggests that sequential treatment with the F(ab9) 2 fragment of anti-FcgRIIB mAb, followed by treatment with the intact mAb, provides a safe way to suppress IgG-mediated anaphylaxis (Fig 3, G) 
